Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Antibody based immune-checkpoint blockade therapy is a major breakthrough in oncology, leading to clinical benefit for cancer patients. Among the growing family of inhibitory receptors, the B and T lymphocyte attenuator (BTLA), which interacts with herpes virus entry mediator (HVEM), is a promising...

Full description

Bibliographic Details
Main Authors: Marta Spodzieja, Sławomir Lach, Justyna Iwaszkiewicz, Valérie Cesson, Katarzyna Kalejta, Daniel Olive, Olivier Michielin, Daniel E Speiser, Vincent Zoete, Laurent Derré, Sylwia Rodziewicz-Motowidło
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5464627?pdf=render

Similar Items

Similar Items